Skip to main content
Translational Vision Science & Technology logoLink to Translational Vision Science & Technology
. 2019 Dec 5;8(6):26. doi: 10.1167/tvst.8.6.26

OCTA-Based Identification of Different Vascular Patterns in Stargardt Disease

Alessandro Arrigo 1,, Francesco Romano 1,2, Emanuela Aragona 1, Carlo di Nunzio 1, Andrea Sperti 1, Francesco Bandello 1, Maurizio Battaglia Parodi 1
PMCID: PMC6900965  PMID: 31832280

Abstract

Purpose

The aim of the present study was to analyze quantitative optical coherence tomography (OCT) and OCT angiography (OCTA) parameters to identify clinically relevant cutoff values able to detect clinically different Stargardt's disease (STGD) subgroups.

Methods

Consecutive STGD patients were recruited and underwent complete ophthalmologic examination, including multimodal imaging. Several quantitative parameters were extracted both from structural OCT and OCTA images and were statistically analyzed. A post hoc analysis was performed to identify a quantitative cutoff able to distinguish two clinically different STGD subgroups. Main outcome measures were total retinal thickness, central macular thickness (CMT), retinal layers thickness, retinal and choroidal hyperreflective foci (HF) number, vessel density (VD), vessel tortuosity (VT), vessel dispersion (Vdisp), and vessel rarefaction (VR) of macular and optic nerve head plexa.

Results

Overall, 54 eyes of 54 STGD patients (18 males) and 54 eyes of 54 healthy age- and sex-matched controls were included in the analysis. All quantitative parameters resulted significantly worse in STGD than controls (P < 0.01). Moreover, a VT cutoff of 5 allowed to distinguish the following two categories: a functionally and anatomically better STGD group and a worse group. BCVA resulted 0.42 ± 0.28 logMAR in the best group versus 1.09 ± 0.36 logMAR in the worst (P < 0.01). Structural OCT and OCTA parameters significantly differed between the two STGD groups.

Conclusions

Quantitative OCTA was able to detect different morphofunctional STGD phenotypes.

Translational Relevance

OCTA-based classification of STGD patients detected different patients' subgroups, differing in terms of morphologic and functional features, with a potential impact on clinical and research settings.

Keywords: Stargardt disease, OCT, OCTA, vessel density, vessel tortuosity, vessel dispersion, vessel rarefaction

Introduction

Stargardt's disease (STGD) is a common hereditary retinal dystrophy leading to irreversible bilateral visual acuity loss.1 It is characterized by a diffusely compromised retinal pigmented epithelium (RPE)/photoreceptor complex, with heterogeneous manifestations detectable both at the macular level and in the middle and extreme periphery.2,3 Recently developed noninvasive imaging technology, principally optical coherence tomography (OCT) and OCT angiography (OCTA), has led to a better understanding of the underlying pathologic mechanisms governing the onset and progression of the atrophic process, revealing a connection with the damage to the retinal and choroidal vascular network.46

The aim of the present study was to analyze quantitative OCTA parameters in order to identify clinically relevant cutoff values.

Materials and Methods

The study was designed as an observational cross-sectional analysis. Consecutive patients affected by STGD were recruited in the Heredodystrophies Unit of the Department of Ophthalmology of San Raffaele Hospital in Milan. Each patient provided signed informed consent before the examination, in accordance with the Declaration of Helsinki. The study was approved by the Ethical Committee of the Vita-Salute San Raffaele University of Milan. The inclusion criteria were as follows: ABCA4 genetically confirmed diagnosis of STGD and age from 18 to 70 years. The following exclusion criteria were applied: refractive errors greater than ±3 diopters (D), increased media opacity, glaucoma and other types of retinal and/or optic nerve diseases (e.g., diabetic retinopathy), any ophthalmic surgery in the last 6 months, any systemic conditions potentially affecting the results of the study.

All the patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA) using standard Early Treatment Diabetic Retinopathy Study charts, slit-lamp evaluation of anterior and posterior segments, intraocular pressure measurement with a Goldmann applanation tonometer, color fundus photography, and fundus autofluorescence. In addition, structural OCT and OCTA images were acquired by means of Heidelberg Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany) and SS-OCT DRI Topcon Triton (Topcon Corporation, Tokyo, Japan), respectively. The OCT acquisition protocol included high-resolution radial and raster scans, while OCTA analysis included 3 × 3- and 4.5 × 4.5-mm scans, centered at the level of both the macula and the optic nerve head. Eye tracking was used to assess possible fixation loss. Only high-quality images, evaluated by means of Topcon index quality (>70), were considered.

We measured retinal layer thickness by means of a high-resolution horizontal structural enhanced-depth imaging (EDI)-OCT scan,7 including total retinal thickness, central macular thickness (CMT), retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL) and ellipsoid zone–retinal pigment epithelium layer (EZ-RPE). Choroidal thickness was also measured. For each measure, four samplings were obtained on the left and four on the right of the foveal, the mean value being used in the analysis. Moreover, hyperreflective foci (HF) (defined as discrete, punctiform, hyperreflective lesions) were measured in the same structural OCT scan, within both the retina and the choroid, but using inverted colors to improve the imaging. HF were analyzed in a region selected on a horizontal structural OCT, including 750 μm on the right and left sides of a vertical line passing through the fovea. Fundus autofluorescence (FAF) images were also used to assess the presence of foveal sparing, defined as the absence of autofluorescence surrounding the fovea by least 180°, not including the fovea.8 A control group of healthy age- and sex-matched subjects underwent the same ophthalmologic assessment.

OCTA images were analyzed by the Topcon full-spectrum, amplitude-decorrelation, angiography algorithm. Each patient contributed with a single eye, which was randomly selected.

The superficial capillary plexuses (SCP), deep capillary plexuses (DCP), and choriocapillaris (CC) were automatically segmented both in the macula and in the optic nerve head; additionally, the radial peripapillary capillary (RPC) plexus was automatically segmented at the level of the optic nerve. For convenience, macular parameters will henceforth be referred to using the prefix “m,” with the prefix “n” applying to the optic nerve head (e.g., mSCP and nSCP for macular and nerve superficial capillary plexuses, respectively).

Each reconstruction was carefully inspected by an expert ophthalmologist (MBP). All reconstructions were exported in .tiff format and loaded in ImageJ software (Bethesda, MD). In-house scripts were built in order to calculate the following parameters: vessel density (VD), vessel tortuosity (VT), vessel dispersion (Vdisp), and vessel rarefaction (VR), with the same approach already adopted.9

The statistical analysis of the quantitative parameters considered, comparing with control values, was performed using the one-way ANOVA test, with Bonferroni correction for multiple comparisons (SPSS, Chicago, IL). Moreover, statistically significant correlations between all considered parameters were assessed by means of Kendall's tau correlation coefficient measurement. We also performed a receiver operating curve (ROC) analysis in order to extract a parameter that could distinguish STGD subgroups differing significantly in terms of BCVA. The statistical significance was set at P < 0.05.

Results

Overall, 54 eyes of 54 STGD patients (18 males) were included in the analysis, and all data were compared with 54 eyes of 54 healthy age- and sex-matched controls. All clinical and imaging findings are extensively reported in Table 1. Duration of STGD, as assessed on the patients' report, was 12.8 ± 10.8 years. The standout finding was STGD patients showed statistically significant worse BCVA, structural OCT parameters, and OCTA parameters. Moreover, we detected significantly higher HF numbers, both within the retina and the choroid in our patients' cohort, with respect to the control group. Partial or complete foveal sparing was detected in 23 of 54 patients (43%). Correlation analyses revealed several statistically significant correlations (Table 2). In more detail, BCVA was influenced by the integrity both of the retinal layers and vascular network. The presence of HF was found to correlate with worse BCVA. Furthermore, both retinal layer thickness and HF number significantly correlated with OCTA parameters. In particular, high VD and VT values were associated with better structural features and lower HF number, whereas high VDisp and VR values were related to worse retinal status and higher HF number. It is worth noting the higher significant correlations with both VD and VT, compared with VDisp and VR parameters. Statistically significant correlations were found when considering macular OCTA parameters alone, optic nerve head parameters showing unremarkable effects (Figs. 1 and 2). Interestingly, retinal layer thickness showed a stronger correlation with VT values than with VD. In addition, as expected, OCTA parameters showed statistically significant correlations between them (P < 0.01). No significant age or duration effect were detected. ROC analysis established a cutoff value based on the VT mean, to separate two subgroups with different BCVA, with both sensitivity and specificity of 0.9. A VT cutoff of 5 created two categories, a functionally and anatomically better STGD group (STGD1) and a worse group (STGD2) (Table 3). Foveal sparing was present in 15 of 35 patients of STGD1 (43%) and in 8 of 19 patients of STGD2 (42%) (P > 0.05), showing no effects on the analyses.

Table 1.

Clinical and Imaging Findings

Parameter
STGD Patients
Controls
P Value
Mean
SD
Mean
SD
Age 43.52 16.39 45.37 17.93 P > 0.05
BCVA, logMAR 0.68 0.44 0.00 0.00 P < 0.01
RNFL 97.86 9.45 106.53 9.63
EZ-RPE 43.87 21.37 73.01 5.55
ONL 26.19 14.10 92.34 7.25
OPL 20.12 9.90 41.51 5.98
INL 33.15 7.71 46.17 6.46
IPL 34.84 8.85 48.21 7.12
GCL 44.21 11.21 62.49 7.48
CMT 103.05 59.03 241.03 11.16
Retinal thickness 224.23 54.24 400.66 19.06
Choroidal thickness 257.01 94.71 322.53 44.37
HF_retina 7.76 7.35 0.00 0.00
HF_choroid 18.26 17.86 0.00 0.00
VD mSCP 0.40 0.02 0.41 0.01
VD mDCP 0.26 0.06 0.43 0.01
VD mCC 0.32 0.16 0.50 0.01
VDisp mSCP 24.62 8.72 10.72 4.15
VDisp mDCP 27.51 8.75 11.45 3.48
VT mSCP 5.31 0.15 7.20 0.31
VT mDCP 4.80 0.50 7.84 0.34
VR mSCP 0.44 0.03 0.39 0.01
VR mDCP 0.47 0.03 0.41 0.01
VD RPC 0.42 0.02 0.44 0.01
VD nSCP 0.41 0.03 0.43 0.01
VD nDCP 0.30 0.02 0.40 0.02
VD nCC 0.51 0.03 0.54 0.03
VDisp RPC 24.78 8.82 10.61 3.70
VDisp nSCP 25.80 11.56 10.35 2.88
VDisp nDCP 27.43 9.72 10.37 3.36
VT RPC 5.64 0.51 7.73 0.30
VT nSCP 4.45 0.26 8.42 0.33
VT nDCP 5.20 0.27 7.06 0.25
VR RPC 0.47 0.02 0.45 0.01
VR nSCP 0.49 0.02 0.44 0.01
VR nDCP 0.43 0.02 0.40 0.01

Table 2.

Correlation Analysis

Parameter
RNFL
EZ−RPE
ONL
INL
IPL
GCL
CMT
Full_Retina
BCVA logMAR
 Kendall's tau coefficient −0.248 −0.939 −0.938 −0.939 −0.941 −0.94 −0.938 −0.938
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

ONL
INL
IPL
GCL
CMT
Full_retina
HF_retina
HF_choroid
EZ-RPE
 Kendall's tau coefficient 0.996 0.995 0.993 0.994 0.998 0.998 −0.548 −0.658
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

INL
IPL
GCL
CMT
Full_retina
HF_retina
HF_choroid
VD mCC
ONL
 Kendall's tau coefficient 0.994 0.994 0.993 0.996 0.997 −0.545 −0.66 0.963
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

IPL
GCL
CMT
Full_retina
HF_retina
HF_choroid
VD mCC
VT mSCP
INL
 Kendall's tau coefficient 0.992 0.993 0.995 0.996 −0.551 −0.661 0.962 0.99
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

GCL
CMT
Full_retina
HF_retina
HF_choroid
VD mCC
VT mSCP
VT mDCP
IPL
 Kendall's tau coefficient 0.991 0.993 0.994 −0.545 −0.663 0.959 0.987 0.992
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

CMT
Full_retina
HF_retina
HF_choroid
VD mCC
VT mSCP
VT mDCP
VT RPC
GCL
 Kendall's tau coefficient 0.994 0.994 −0.548 −0.662 0.961 0.989 0.993 0.993
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

Full_retina
HF_retina
HF_choroid
VD mCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
CMT
 Kendall's tau coefficient 0.998 −0.546 −0.658 0.964 0.991 0.996 0.995 −0.951
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

HF_retina
HF_choroid
VD mCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
VR mDCP
Full_retina
 Kendall's tau coefficient −0.547 −0.658 0.965 0.991 0.998 0.997 −0.951 −0.961
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

HF_choroid
VD mCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
VR mDCP
VR RPC
HF_retina
 Kendall's tau coefficient 0.665 −0.516 −0.554 −0.547 −0.547 0.535 0.549 0.526
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VD mCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
VR mDCP
VR RPC

HF_choroid
 Kendall's tau coefficient −0.625 −0.657 −0.657 −0.657 0.628 0.663 0.679
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

Figure 1.

Figure 1

Macular OCTA in STGD. SCP (A) and DCP (B) appear evidently rarefied in STGD. Furthermore, CC (C) results almost absent, with clear exposure of choroidal vessels. SCP, DCP, and CC plexa of a healthy control are shown in (D–F), respectively.

Figure 2.

Figure 2

Optic nerve head OCTA in STGD. If comparing a STGD patient with a healthy control, RPC (A), SCP (B), and DCP (C) appear evidently rarefied in STGD. Moreover, also CC plexus shows signs of perfusion lacks (D). RPC, SCP, DCP, and CC plexa of a healthy control are shown in (E–H), respectively.

Table 3.

OCTA VT Cutoff Analysis (VT = 5)

Parameter
Mean ± SD
Comparison
P Values
Age
 STGD1 44 ± 15 STGD1 vs. STGD2 >0.05
 STGD2 44 ± 19 STGD1 vs. Controls >0.05
 Controls 45 ± 17 STGD2 vs. Controls >0.05
BCVA, logMAR
 STGD1 0.42 ± 0.28 STGD1 vs. STGD2 <0.01
 STGD2 1.09 ± 0.36 STGD1 vs. Controls <0.01
 Controls 0.0 ± 0.0 STGD2 vs. Controls <0.01
RNFL
 STGD1 98 ± 9 STGD1 vs. STGD2 >0.05
 STGD2 98 ± 10 STGD1 vs. controls <0.01
 Controls 107 ± 10 STGD2 vs. Controls <0.01
CMT
 STGD1 129 ± 58 STGD1 vs. STGD2 <0.01
 STGD2 65 ± 48 STGD1 vs. Controls <0.01
 Controls 240 ± 11 STGD2 vs. Controls <0.01
Full retinal thickness
 STGD1 248 ± 52 STGD1 vs. STGD2 <0.01
 STGD2 189 ± 42 STGD1 vs. Controls <0.01
 Controls 403 ± 16 STGD2 vs. Controls <0.01
CT
 STGD1 268 ± 92 STGD1 vs. STGD2 >0.05
 STGD2 242 ± 99 STGD1 vs. controls <0.05
 Controls 322 ± 45 STGD2 vs. controls <0.01
EZ-RPE
 STGD1 55 ± 19 STGD1 vs. STGD2 <0.01
 STGD2 26 ± 13 STGD1 vs. controls <0.01
 Controls 73 ± 6 STGD2 vs. controls <0.01
ONL
 STGD1 33 ± 12 STGD1 vs. STGD2 <0.01
 STGD2 17 ± 15 STGD1 vs. controls <0.01
 Controls 93 ± 7 STGD2 vs. controls <0.01
OPL
 STGD1 21 ± 12 STGD1 vs. STGD2 <0.01
 STGD2 19 ± 7 STGD1 vs. controls <0.01
 Controls 42 ± 6 STGD2 vs. controls <0.01
INL
 STGD1 37 ± 7 STGD1 vs. STGD2 <0.01
 STGD2 27 ± 4 STGD1 vs. controls <0.01
 Controls 47 ± 6 STGD2 vs. controls <0.01
IPL
 STGD1 39 ± 8 STGD1 vs. STGD2 <0.01
 STGD2 27 ± 4 STGD1 vs. controls <0.01
 Controls 49 ± 7 STGD2 vs. controls <0.01
GCL
 STGD1 50 ± 8 STGD1 vs. STGD2 <0.01
 STGD2 34 ± 7 STGD1 vs. controls <0.01
 Controls 63 ± 7 STGD2 vs. controls <0.01
HF_retina
 STGD1 7 ± 7 STGD1 vs. STGD2 <0.05
 STGD2 10 ± 7 STGD1 vs. controls <0.01
 Controls 0 ± 0 STGD2 vs. controls <0.01
HF_choroid
 STGD1 11 ± 11 STGD1 vs. STGD2 <0.01
 STGD2 30 ± 20 STGD1 vs. controls <0.01
 Controls 0 ± 0 STGD2 vs. controls <0.01
VD mSCP
 STGD1 0.40 ± 0.02 STGD1 vs. STGD2 >0.05
 STGD2 0.40 ± 0.02 STGD1 vs. controls <0.01
 Controls 0.41 ± 0.01 STGD2 vs. controls <0.01
VD mDCP
 STGD1 0.26 ± 0.06 STGD1 vs. STGD2 >0.05
 STGD2 0.28 ± 0.07 STGD1 vs. controls <0.01
 Controls 0.43 ± 0.01 STGD2 vs. controls <0.01
VD mCC
 STGD1 0.42 ± 0.03 STGD1 vs. STGD2 <0.01
 STGD2 0.17 ± 0.17 STGD1 vs. controls <0.01
 Controls 0.50 ± 0.01 STGD2 vs. controls <0.01
VD RPC
 STGD1 0.42 ± 0.02 STGD1 vs. STGD2 >0.05
 STGD2 0.42 ± 0.02 STGD1 vs. controls <0.01
 Controls 0.44 ± 0.01 STGD2 vs. controls <0.01
VD nSCP
 STGD1 0.41 ± 0.03 STGD1 vs. STGD2 >0.05
 STGD2 0.40 ± 0.04 STGD1 vs. controls >0.05
 Controls 0.43 ± 0.01 STGD2 vs. controls <0.05
VD nDCP
 STGD1 0.30 ± 0.02 STGD1 vs. STGD2 >0.05
 STGD2 0.30 ± 0.03 STGD1 vs. controls <0.01
 Controls 0.40 ± 0.02 STGD2 vs. controls <0.01
VD nCC
 STGD1 0.50 ± 0.02 STGD1 vs. STGD2 <0.01
 STGD2 0.52 ± 0.04 STGD1 vs. controls <0.01
 Controls 0.54 ± 0.03 STGD2 vs. controls <0.01
VD mean
 STGD1 0.39 ± 0.01 STGD1 vs. STGD2 <0.01
 STGD2 0.36 ± 0.03 STGD1 vs. controls <0.01
 Controls 0.45 ± 0.01 STGD2 vs. controls <0.01
Vdisp mSCP
 STGD1 23.86 ± 6.43 STGD1 vs. STGD2 >0.05
 STGD2 25.54 ± 11.83 STGD1 vs. controls <0.01
 Controls 10.53 ± 4.08 STGD2 vs. controls <0.01
Vdisp mDCP
 STGD1 27.71 ± 9.61 STGD1 vs STGD2 >0.05
 STGD2 26.50 ± 7.54 STGD1 vs. controls <0.01
 Controls 11.36 ± 3.50 STGD2 vs. controls <0.01
Vdisp RPC
 STGD1 26.71 ± 9.46 STGD1 vs. STGD2 <0.01
 STGD2 20.62 ± 6.74 STGD1 vs. controls <0.01
 Controls 10.67 ± 3.75 STGD2 vs. controls <0.01
Vdisp nSCP
 STGD1 28.41 ± 12.61 STGD1 vs. STGD2 <0.01
 STGD2 20.40 ± 7.72 STGD1 vs. controls <0.01
 Controls 10.40 ± 2.92 STGD2 vs. controls <0.01
Vdisp nDCP
 STGD1 28.37 ± 9.49 STGD1 vs. STGD2 >0.05
 STGD2 24.75 ± 10.80 STGD1 vs. controls <0.01
 Controls 10.50 ± 3.34 STGD2 vs. controls <0.01
VDisp mean
 STGD1 27.01 ± 6.58 STGD1 vs. STGD2 <0.05
 STGD2 23.56 ± 5.61 STGD1 vs. controls <0.01
 Controls 10.69 ± 1.37 STGD2 vs. controls <0.01
VT mSCP
 STGD1 5.39 ± 0.11 STGD1 vs. STGD2 >0.05
 STGD2 5.27 ± 0.44 STGD1 vs. controls <0.01
 Controls 7.20 ± 0.31 STGD2 vs. controls <0.01
VT mDCP
 STGD1 5.08 ± 0.31 STGD1 vs. STGD2 >0.05
 STGD2 4.46 ± 0.84 STGD1 vs. controls <0.01
 Controls 7.85 ± 0.35 STGD2 vs. controls <0.01
VT RPC
 STGD1 5.93 ± 0.30 STGD1 vs. STGD2 >0.05
 STGD2 5.24 ± 0.66 STGD1 vs. controls <0.01
 Controls 7.73 ± 0.30 STGD2 vs. controls <0.01
VT nSCP
 STGD1 4.49 ± 0.30 STGD1 vs. STGD2 >0.05
 STGD2 4.56 ± 0.87 STGD1 vs. controls <0.01
 Controls 8.43 ± 0.33 STGD2 vs. controls <0.01
VT nDCP
 STGD1 5.24 ± 0.30 STGD1 vs. STGD2 >0.05
 STGD2 5.19 ± 0.42 STGD1 vs. controls <0.01
 Controls 7.07 ± 0.25 STGD2 vs. controls <0.01
VT mean
 STGD1 5.23 ± 0.15 STGD1 vs. STGD2 <0.01
 STGD2 4.94 ± 0.61 STGD1 vs. controls <0.01
 Controls 7.66 ± 0.23 STGD2 vs. controls <0.01
VR mSCP
 STGD1 0.43 ± 0.02 STGD1 vs. STGD2 <0.01
 STGD2 0.47 ± 0.03 STGD1 vs. controls <0.01
 Controls 0.39 ± 0.01 STGD2 vs. controls <0.01
VR mDCP
 STGD1 0.45 ± 0.02 STGD1 vs. STGD2 <0.01
 STGD2 0.50 ± 0.03 STGD1 vs. controls <0.01
 Controls 0.41 ± 0.01 STGD2 vs. controls <0.01
VR RPC
 STGD1 0.46 ± 0.01 STGD1 vs. STGD2 <0.01
 STGD2 0.49 ± 0.01 STGD1 vs. controls <0.01
 Controls 0.44 ± 0.01 STGD2 vs. controls <0.01
VR nSCP
 STGD1 0.49 ± 0.02 STGD1 vs. STGD2 <0.01
 STGD2 0.48 ± 0.02 STGD1 vs. controls <0.01
 Controls 0.44 ± 0.01 STGD2 vs. controls <0.01
VR nDCP
 STGD1 0.43 ± 0.02 STGD1 vs. STGD2 <0.01
 STGD2 0.42 ± 0.02 STGD1 vs. controls <0.01
 Controls 0.40 ± 0.01 STGD2 vs. controls <0.01
VR mean
 STGD1 0.45 ± 0.01 STGD1 vs. STGD2 <0.01
 STGD2 0.47 ± 0.02 STGD1 vs. controls <0.01
 Controls 0.42 ± 0.01 STGD2 vs. controls <0.01

Table 2.

Extended

Parameter
HF_retina
HF_choroid
VD mCC
VD nCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
BCVA logMAR
 Kendall's tau coefficient 0.56 0.697 −0.903 0.366 −0.943 −0.939 −0.938 0.925
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VD mCC
VT mSCP
VT mDCP
VT RPC
VR mSCP
VR mDCP
VR RPC
VT Mean
EZ-RPE
 Kendall's tau coefficient 0.964 0.992 0.997 0.995 −0.952 −0.962 −0.913 0.735
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VT mSCP
VT mDCP
VT RPC
VR mSCP
VR mDCP
VR RPC
VT Mean
VR Mean
ONL
 Kendall's tau coefficient 0.991 0.997 0.997 −0.951 −0.963 −0.913 0.735 −0.725
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VT mDCP
VT RPC
VR mSCP
VR mDCP
VR RPC
VT Mean
VR Mean

INL
 Kendall's tau coefficient 0.995 0.993 −0.952 −0.961 −0.914 0.736 −0.726
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VT RPC
VR mSCP
VR mDCP
VR RPC
VT Mean
VR Mean


IPL
 Kendall's tau coefficient 0.993 −0.953 −0.961 −0.918 0.738 −0.726
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01

VR mSCP
VR mDCP
VR RPC
VT Mean
VR Mean



GCL
 Kendall's tau coefficient −0.952 −0.962 −0.917 0.731 −0.729
P value <0.01 <0.01 <0.01 <0.01 <0.01

VR mDCP
VR RPC
VT Mean
VR Mean




CMT
 Kendall's tau coefficient −0.962 −0.914 0.735 −0.724
P value <0.01 <0.01 <0.01 <0.01

VR RPC
VD Mean
VT Mean
VR Mean




Full_retina
 Kendall's tau coefficient −0.913 0.373 0.738 −0.724
P value <0.01 <0.01 <0.01 <0.01









HF_retina
 Kendall's tau coefficient
P value









HF_choroid
 Kendall's tau coefficient
P value

Table 2.

Extended

Parameter
VR mDCP
BCVA logMAR
 Kendall's tau coefficient 0.939
P value <0.01

VR Mean
EZ-RPE
 Kendall's tau coefficient −0.723
P value <0.01


ONL
 Kendall's tau coefficient
P value


INL
 Kendall's tau coefficient
P value


IPL
 Kendall's tau coefficient
P value


GCL
 Kendall's tau coefficient
P value


CMT
 Kendall's tau coefficient
P value


Full_retina
 Kendall's tau coefficient
P value


HF_retina
 Kendall's tau coefficient
P value


HF_choroid
 Kendall's tau coefficient
P value

Discussion

STGD is a complex disease primarily associated with RPE/photoreceptor dysfunction and is accompanied by a compromised vascular network, which can be noninvasively analyzed by OCTA.6 In particular, macular CC alterations represent a key element contributing to outer retinal atrophy.4

The aim of the present study was to analyze both retinal layer and vascular network changes in STGD. A significant thinning of inner and outer retinal layers, together with the presence of relevant alterations of the retinal vascular network were found, providing further confirmation of the CC macular damage. Although significant dysfunction of the optic nerve head plexa was detected, these changes may be interpreted as a consequence of modifications to the retina. Quantitative OCTA parameters, including VT, VDisp, and VR, enabled the involvement of the retinal vascular network in STGD to be described in greater detail. In particular, retinal plexa appeared rarer and more disorganized than in controls, VT reduction representing the consequence of reduced blood flow perfusion.9

The dysfunction present throughout the retinal vascular network may be due to the primary RPE/photoreceptor damage. Indeed, the RPE is essential to the physiologic release of growth factors, including VEGF, which guarantee the trophism of retinal vessels and CC, along with the regulation of metabolic exchanges through the blood–retinal barrier (Le YZ, et al. IOVS. 2008;49:E−Abstract 857).10 With regard to inner retinal thinning, this finding might be explained as inner retinal cell damage caused by anterograde degeneration, taking into account the exclusive expression of the ABCA4 gene in the RPE/photoreceptor complex.11 Alternatively, the loss of trophic stimuli from RPE cells, in addition to the retinal vascular network deficiency, may contribute to inner retinal degeneration and thinning. The results of the correlation analysis, especially the strong correlation revealed between retinal layer thickness and VT, further underline the influence of the impaired blood supply in the progression of the degenerative process occurring in STGD.

The higher number of retinal and choroidal HF in STGD patients has already been described12 and represents an imaging biomarker of the disease's activity, as reported in other conditions.13

The most interesting findings of the present paper are the results of the cutoff analyses of OCTA parameters. A VT cutoff value of 5, obtained from the mean of the values of all retinal plexa, was able to identify two different STGD groups on the basis of the BCVA. These patients' subgroups also differed in terms of retinal layer thickness and OCTA parameters, thus enabling us to divide our patients' cohort into better and worse morphofunctional groups. Interestingly, STGD1 and STGD2 subgroups did not differ significantly in terms of foveal sparing, suggesting that other factors besides the atrophic changes of the fovea contribute to the BCVA loss. We hypothesize that the more extensively dysfunctional vascular network typical of STGD2 is responsible for an overall decrease in macular functionality. In other words, assuming the same degree of foveal involvement, a more trophic vascular network leads to a better retinal function. Although obtained from what is only a pilot study, our findings may have important clinical implications. In particular, patient evaluation in clinical practice might benefit from the information provided by this kind of analysis, enabling different clinical phenotypes to be identified. Furthermore, viewed in the context of clinical trials designed to test potential drugs, this approach might have a role in patient selection and in assessing clinical and anatomic outcomes.

Our study has undoubted limitations. Both OCT and OCTA analyses are known to be potentially affected by a number of artifacts,14,15 so we adopted all possible precautions to minimize their potential effect on data analysis. We are also aware that our imaging-based analysis might certainly benefit from histopathologic validation. Last, our cases were insufficient to draw definitive conclusions and it would therefore be advisable to carry out a longitudinal follow-up of patients in order to confirm our data.

In essence, our study reveals that extensive changes both in the retinal vascular network and in the retinal layers can be detected in STGD. A quantitative cutoff based on VT can separate two different morphofunctional phenotypes.

We believe a quantitative assessment might contribute to more accurate patients' categorization in a future scenario that sees possible new drugs combining with the introduction of artificial intelligence–based techniques to identify and treat STGD. Further studies are warranted to provide further support to the present findings.

Acknowledgments

Disclosure: A. Arrigo, None; F. Romano, None; E. Aragona, None; C. di Nunzio, None; A. Sperti, None; F. Bandello, Allergan Inc, Bayer Shering-Pharma, Hoffmann-La-Roche, NTC Pharma, Novartis, SIFI, SOOFT, Thrombogenics, Zeiss (C); M. Battaglia Parodi, None

References

  • 1.Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2017;255:1057–1062. doi: 10.1007/s00417-017-3619-8. [DOI] [PubMed] [Google Scholar]
  • 2.Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101:25–30. doi: 10.1136/bjophthalmol-2016-308823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Klufas MA, Tsu I, Sadda SR, Hosseini H, Schwartzm SD. Ultrawidefield autofluoresence in ABCA4 Stargardt disease. Retina. 2018;38:403–415. doi: 10.1097/IAE.0000000000001567. [DOI] [PubMed] [Google Scholar]
  • 4.Pellegrini M, Acquistapace A, Oldani M, et al. Dark atrophy: an optical coherence tomography angiography study. Ophthalmology. 2016;123:1879–1886. doi: 10.1016/j.ophtha.2016.05.041. [DOI] [PubMed] [Google Scholar]
  • 5.Mastropasqua R, Toto L, Borrelli E, et al. Optical coherence tomography angiography findings in Stargardt disease. PLoS One. 2017;12:e0170343. doi: 10.1371/journal.pone.0170343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Battaglia Parodi M, Cicinelli MV, Rabiolo A, Pierro L, Bolognesi G, Bandello F. Vascular abnormalities in patients with Stargardt disease assessed with optical coherence tomography angiography. Br J Ophthalmol. 2017;101:780–785. doi: 10.1136/bjophthalmol-2016-308869. [DOI] [PubMed] [Google Scholar]
  • 7.Invernizzi A, Pellegrini M, Acquistapace A, et al. Normative data for retinal-layer thickness maps generated by spectral-domain OCT in a white population. Ophthalmol Retina. 2018;2:808–815. doi: 10.1016/j.oret.2017.12.012. [DOI] [PubMed] [Google Scholar]
  • 8.Van Huet RA, Bax NM, Westeneng-Van Haaften SC, et al. Foveal sparing in Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55:7467–7478. doi: 10.1167/iovs.13-13825. [DOI] [PubMed] [Google Scholar]
  • 9.Arrigo A, Aragona E, Capone L, et al. Advanced optical coherence tomography angiography analysis of age-related macular degeneration complicated by onset of unilateral choroidal neovascularization. Am J Ophthalmol. 2018;195:233–242. doi: 10.1016/j.ajo.2018.08.001. [DOI] [PubMed] [Google Scholar]
  • 10.Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009;106:18751–18756. doi: 10.1073/pnas.0905010106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Molday RS, Zhong M, Quazi F. The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta. 2009;1791:573–583. doi: 10.1016/j.bbalip.2009.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Battaglia Parodi M, Sacconi R, Romano F, Bandello F. Hyperreflective foci in Stargardt disease: 1-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2019;257:41–48. doi: 10.1007/s00417-018-4167-6. [DOI] [PubMed] [Google Scholar]
  • 13.Battaglia Parodi M, Arrigo A, Romano F, et al. Hyperreflective foci number correlates with choroidal neovascularization activity in angioid streaks. Invest Ophthalmol Vis Sci. 2018;59:3314–3319. doi: 10.1167/iovs.18-24291. [DOI] [PubMed] [Google Scholar]
  • 14.Spaide RF, Fujimoto JG, Waheed NK. Image artifacts in optical coherence tomography angiography. Retina. 2015;35:2163–2180. doi: 10.1097/IAE.0000000000000765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55. doi: 10.1016/j.preteyeres.2017.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Translational Vision Science & Technology are provided here courtesy of Association for Research in Vision and Ophthalmology

RESOURCES